322 related articles for article (PubMed ID: 31188813)
1. Toxicities of checkpoint inhibitors: causes and management.
Postow MA
Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
[No Abstract] [Full Text] [Related]
2. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
3. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
4. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors.
Hui E
J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
[TBL] [Abstract][Full Text] [Related]
6. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management.
Grover S; Rahma OE; Hashemi N; Lim RM
Am Soc Clin Oncol Educ Book; 2018 May; 38():13-19. PubMed ID: 30231401
[TBL] [Abstract][Full Text] [Related]
8. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
11. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
12. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
Chow LQ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
[TBL] [Abstract][Full Text] [Related]
13. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
Dhariwal R; Pindoria N; Dasgupta P; Khan MS
BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
[No Abstract] [Full Text] [Related]
14. Treatment of PD-1/PD-L1 Inhibitor-Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas.
Crow LD; Perkins I; Twigg AR; Fassett MS; LeBoit PE; Berger TG; Khodosh R
JAMA Dermatol; 2020 May; 156(5):598-600. PubMed ID: 32211828
[No Abstract] [Full Text] [Related]
15. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
16. Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer.
Brahmer JR
Clin Adv Hematol Oncol; 2016 Mar; 14(3):165-7. PubMed ID: 27058029
[No Abstract] [Full Text] [Related]
17. [Quality of life in immune checkpoint inhibitors trials].
Coquan E; Joly F
Bull Cancer; 2020; 107(7-8):830-842. PubMed ID: 32758364
[TBL] [Abstract][Full Text] [Related]
18. [Checkpoint inhibitors neurological side effects].
Suay G; Bataller L
Rev Neurol; 2019 Apr; 68(7):301-311. PubMed ID: 30906980
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis.
Sorotsky H; Hogg D; Amir E; Araujo DV
JAMA Netw Open; 2019 Nov; 2(11):e1914816. PubMed ID: 31702796
[TBL] [Abstract][Full Text] [Related]
20. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
